Equities research analysts forecast that Curis, Inc. (NASDAQ:CRIS) will announce ($0.09) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Curis’ earnings, with estimates ranging from ($0.11) to ($0.07). Curis reported earnings of ($0.12) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 25%. The company is expected to report its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Curis will report full-year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.42) to ($0.35). For the next year, analysts anticipate that the firm will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.49) to ($0.29). Zacks’ EPS averages are an average based on a survey of analysts that follow Curis.

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. During the same period in the prior year, the company posted ($0.09) earnings per share. The firm’s quarterly revenue was up 23.5% on a year-over-year basis.

CRIS has been the subject of several research reports. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Curis presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Several institutional investors and hedge funds have recently bought and sold shares of CRIS. Bank of America Corp DE lifted its stake in shares of Curis by 58.7% in the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 13,448 shares during the period. Prudential Financial Inc. acquired a new position in shares of Curis in the 1st quarter valued at $105,000. OxFORD Asset Management LLP acquired a new position in shares of Curis in the 2nd quarter valued at $115,000. Dynamic Technology Lab Private Ltd lifted its stake in shares of Curis by 22.3% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 7,638 shares during the period. Finally, Voya Investment Management LLC lifted its stake in shares of Curis by 21.8% in the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares during the period. Hedge funds and other institutional investors own 50.94% of the company’s stock.

Shares of Curis (NASDAQ CRIS) opened at 1.6032 on Tuesday. The stock’s market capitalization is $230.67 million. Curis has a one year low of $1.47 and a one year high of $3.72. The firm’s 50-day moving average is $1.81 and its 200-day moving average is $2.12.

TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/22/curis-inc-cris-expected-to-post-earnings-of-0-09-per-share.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.